Pfizer Vs. Amgen: Bet That Pfizer’s Seagen Integration Leads to Long-Term Oncology Alpha Over Amgen

Pfizer (NYSE: PFE | PFE Price Prediction) and Amgen (NASDAQ: AMGN) both reported Q1 2026 results this quarter, and the numbers reveal two very different bets on the future of oncology. Pfizer is monetizing its Seagen deal today. Amgen is defending a biosimilar cliff while spending to rebuild growth from scratch.

Padcev Carries Pfizer. Biosimilars Bite Amgen.

Pfizer’s oncology franchise pulled in $3.83 billion, up 9% year over year, led by Seagen’s crown jewel Padcev at $591 million (+39%) on first-line urothelial share gains. Lorbrena jumped 37%, Orgovyx 43%, and total launched and acquired products grew 22% operationally. That is real commercial momentum.

Amgen’s story is bifurcated. IMDELLTRA soared 219% to $258 million and UPLIZNA jumped 188%, yet legacy supportive care crumbled. Prolia fell 34% to $727 million, XGEVA dropped 27%, and Enbrel slid 37% under Medicare Part D price setting. CEO Robert Bradway framed it optimistically, noting “16 brands achieving double-digit growth, enabling us to grow through expected patent expirations”. The math is tighter than the tone suggests.

Monetizing Assets vs. Rebuilding a Base

Albert Bourla said Pfizer is “off to a strong start in 2026” and singled out oncology and obesity as areas where he expects Pfizer to lead. That confidence rests on existing revenue streams already booking growth. Padcev’s Phase 3 EV-304 trial showed a 47% reduction in tumor recurrence, progression or death in MIBC patients, with a PDUFA target of August 17, 2026.

Amgen’s counter is capital-intensive. MariTide obesity trials, Xaluritamig in prostate cancer, and biosimilars for KEYTRUDA and OPDIVO all require years of spend before payback. Debt sits at $57.3 billion. Amgen is pivoting heavy capital into high-risk, early-stage platforms just to defend its baseline.

The Padcev PDUFA and MariTide Readouts Will Set the Tone

I will be watching Padcev’s August 17 PDUFA decision, Elrexfio’s myeloma expansion, and whether Pfizer can hold its reaffirmed $59.5 to $62.5 billion revenue guide against a $1.5 billion generic headwind. For Amgen, MariTide Phase 3 readouts and the pace of Prolia erosion matter most. Any acceleration there pressures the $37.1 to $38.5 billion full-year guide.

Why I Lean Toward Pfizer for Oncology Alpha

Personally, I lean Pfizer here. You are paying a forward P/E of 8 for a business collecting cash today from Seagen assets, versus 17 for Amgen’s rebuild story. The 7.07% dividend yield compensates holders during the wait. Amgen’s stock has run 14.1% YTD while Pfizer is flat at -0.07%, which is exactly why I find PFE more interesting now. Investors focused on the growth narrative who can tolerate biosimilar drag will find Amgen’s setup more compelling. If input costs stay volatile and MFN pricing tightens, the cheaper multiple and the working oncology franchise become more attractive on a relative basis.

Contact [email protected] for any questions or corrections.